Allergan PLC is the dominant player in medical aesthetics with its blockbuster wrinkle-reducing neurotoxin Botox (onabotulinumtoxinA) and portfolio of injectables, implants and other products, but it is not alone. Merz Pharmaceuticals GMBH and Galderma SA also have spent years curating collections of products to entice doctors who are seeing surging interest from patients in non-invasive procedures to improve their appearance.
One of the biggest challenges for all biopharma players in medical aesthetics is to grow the overall market. Allergan's research...